Movement Alert｜Illumina Rises 5.25% in Regular Trading, RBC Sees Durable Clinical Sequencing Growth as Competition Fades

Market Focus08-20 22:58

On August 20, Illumina rose 5.25% in regular trading, trading at approximately $215.77/share with turnover of $207 million, extending the prior session's strong performance.

The rally was driven by a recent RBC Capital Markets report highlighting that Illumina is building sustained clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can achieve durable mid-teens growth, primarily driven by oncology testing volume increases and easing pricing headwinds. The firm maintains an Outperform rating with a $230 price target. RBC noted that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.

The broader Life Sciences Tools and Services sector provided additional support, with Tempus AI up 10.02%, Personalis up 7.05%, Danaher up 3.29%, and Thermo Fisher Scientific up 2.31%, reflecting strong industry-wide momentum in genomics and precision medicine names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155359929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155359929","market":"us","top_or_hot":-1,"title":"Movement Alert｜Illumina Rises 5.25% in Regular Trading, RBC Sees Durable Clinical Sequencing Growth as Competition Fades","media":"Market Focus","content":"<p><p>On August 20, Illumina rose 5.25% in regular trading, trading at approximately $215.77/share with turnover of $207 million, extending the prior session's strong performance.</p><p>The rally was driven by a recent RBC Capital Markets report highlighting that Illumina is building sustained clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can achieve durable mid-teens growth, primarily driven by oncology testing volume increases and easing pricing headwinds. The firm maintains an Outperform rating with a $230 price target. RBC noted that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.</p><p>The broader Life Sciences Tools and Services sector provided additional support, with Tempus AI up 10.02%, Personalis up 7.05%, Danaher up 3.29%, and Thermo Fisher Scientific up 2.31%, reflecting strong industry-wide momentum in genomics and precision medicine names.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Illumina Rises 5.25% in Regular Trading, RBC Sees Durable Clinical Sequencing Growth as Competition Fades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Illumina Rises 5.25% in Regular Trading, RBC Sees Durable Clinical Sequencing Growth as Competition Fades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, Illumina rose 5.25% in regular trading, trading at approximately $215.77/share with turnover of $207 million, extending the prior session's strong performance.</p><p>The rally was driven by a recent RBC Capital Markets report highlighting that Illumina is building sustained clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can achieve durable mid-teens growth, primarily driven by oncology testing volume increases and easing pricing headwinds. The firm maintains an Outperform rating with a $230 price target. RBC noted that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.</p><p>The broader Life Sciences Tools and Services sector provided additional support, with Tempus AI up 10.02%, Personalis up 7.05%, Danaher up 3.29%, and Thermo Fisher Scientific up 2.31%, reflecting strong industry-wide momentum in genomics and precision medicine names.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1155359929","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155359929","pubTimestamp":1787237895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, Illumina rose 5.25% in regular trading, trading at approximately $215.77/share with turnover of $207 million, extending the prior session's strong performance.The rally was driven by a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"动态警报|Illumina 在常规交易中上涨 5.25%，RBC 预计随着竞争消退，临床测序将持续增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"On August 20, Illumina rose 5.25% in regular trading, trading at approximately $215.77/share with turnover of $207 million, extending the prior session's strong performance.The rally was driven by a recent RBC Capital Markets report highlighting that Illumina is building sustained clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can achieve durable mid-teens growth, primarily driven by oncology testing volume increases and easing pricing headwinds. The firm maintains an Outperform rating with a $230 price target. RBC noted that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.The broader Life Sciences Tools and Services sector provided additional support, with Tempus AI up 10.02%, Personalis up 7.05%, Danaher up 3.29%, and Thermo Fisher Scientific up 2.31%, reflecting strong industry-wide momentum in genomics and precision medicine names.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155359929","isCrawlerRequest":true}